Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Terminated 3

Sponsor Class

INDUSTRY 17OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 2Lymphoid 1

Conditions

Multiple Myeloma 2Plasmablastic Lymphoma 1

Interventions

Cyclophosphamide 548pembrolizumab 385Radiotherapy 363Bevacizumab 360Carboplatin 351Rituximab 315Cisplatin 300Gemcitabine 297Paclitaxel 288Dexamethasone 272Docetaxel 271fludarabine phosphate 241Doxorubicin 231Nivolumab 220Etoposide 209Cytarabine 203Lenalidomide 201fludarabine 191Oxaliplatin 191Fluorouracil 190Melphalan 189Filgrastim 188Capecitabine 175Calcium Dobesilate 172Radiosurgery 167Erlotinib Hydrochloride 167Methotrexate 163Bortezomib 162Granulocyte Colony-Stimulating Factor 154Whole-Body Irradiation 144

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Has results × belantamab mafodotin × Clear all
NCT04676360 2026-03-13

Belantamab Mafodotin In Plasmablastic Lymphoma & ALK+ Large B-Cell Lymphoma

Massachusetts General Hospital

Phase 2 Terminated
10 enrolled 11 charts
Lymphoid

Plasmablastic Lymphoma

NCT04896658 2025-04-03

Belantamab Mafodotin, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma

University of Maryland, Baltimore

Phase 1/2 Terminated
10 enrolled 14 charts
Plasma cell

Multiple Myeloma

NCT05117008 2025-01-28

EMBRACE

Medical College of Wisconsin

Phase 2 Terminated
1 enrolled 5 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡